Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CymaBay Therapeutics Inc. - Common Stock (NQ: CBAY ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 32.36 (5) Ask (Size) 32.49 (100) Prev. Close 32.48 Today's Range N/A - N/A 52wk Range 22.11 - 32.49 Shares Outstanding 84,677,939 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21 March 21, 2024 Via Investor Brand Network Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production March 15, 2024 Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... Via Benzinga Performance More News Read More Top 3 Health Care Stocks That Are Ticking Portfolio Bombs March 14, 2024 Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL) February 29, 2024 From Brodsky & Smith LLC Via GlobeNewswire CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21 February 21, 2024 Via Investor Brand Network CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13 February 13, 2024 Via Investor Brand Network CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25 January 25, 2024 Via Investor Brand Network CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY February 16, 2024 From Kahn Swick & Foti, LLC Via Business Wire Analysts see over 50% gains in these 2 mid-cap biotech stocks February 14, 2024 Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst February 13, 2024 Via Benzinga Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high February 13, 2024 Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities 6 Analysts Have This to Say About CymaBay Therapeutics December 15, 2023 Via Benzinga Recap: CymaBay Therapeutics Q3 Earnings November 07, 2023 Via Benzinga Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B February 12, 2024 Via Benzinga Topics Stocks Exposures US Equities Dow Up Triple Digits, Hits Fresh Highs February 12, 2024 Via Talk Markets Topics Economy Stocks Exposures Interest Rates US Equities BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB) February 12, 2024 From Brodsky & Smith LLC Via GlobeNewswire Why is CymaBay (CBAY) Stock Up 25% Today? February 12, 2024 Via InvestorPlace CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday February 12, 2024 Via Benzinga Topics Stocks Exposures US Equities Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics February 12, 2024 Via Benzinga CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders February 12, 2024 From Halper Sadeh LLC Via Business Wire Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B February 12, 2024 Via Benzinga Exposures Product Safety CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition February 12, 2024 Via Investor's Business Daily Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics February 12, 2024 From Gilead Sciences, Inc. Via Business Wire Why CymaBay Morphed From Dollar Stock To Biotech Rocket December 28, 2023 Via Investor's Business Daily Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know November 08, 2023 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
